Gadolinium-based Contrast Agents - Review of Recent Literature on Magnetic Resonance Imaging Signal Intensity Changes and Tissue Deposits, with Emphasis on Pediatric Patients

Overview

Journal Pediatr Radiol

Specialty Pediatrics

Date 2019 Mar 30

PMID 30923876

Citations 27

Authors

Einat Blumfield

David W Swenson

Ramesh S Iyer

A Luana Stanescu

Affiliations

Soon will be listed here.

Abstract

Gadolinium has been used as a base for contrast agents in MRI for the last three decades. Numerous studies over the last 4 years have reported increased signal intensity in deep brain nuclei in non-contrast MRI images following gadolinium-based contrast agent (GBCA) administration. Pathology studies performed on adults and children, and rodent necropsy studies have also shown gadolinium deposition in brain and other tissues after GBCA administration. The purpose of this review was to summarize and discuss the knowledge gained from these reports and the relevance for imaging pediatric patients.

Citing Articles

Fetal Safety in MRI During Pregnancy: A Comprehensive Review.

Puris G, Chetrit A, Katorza E Diagnostics (Basel). 2025; 15(2).

PMID: 39857092 PMC: 11765095. DOI: 10.3390/diagnostics15020208.

A deep learning model to enhance the classification of primary bone tumors based on incomplete multimodal images in X-ray, CT, and MRI.

Song L, Li C, Tan L, Wang M, Chen X, Ye Q Cancer Imaging. 2024; 24(1):135.

PMID: 39390604 PMC: 11468403. DOI: 10.1186/s40644-024-00784-7.

Gadolinium Contrast Agent Deposition in Children.

Ouyang M, Bao L J Magn Reson Imaging. 2024; 61(1):70-82.

PMID: 38597340 PMC: 11645493. DOI: 10.1002/jmri.29389.

Multivalent Fluorinated Nanorings for On-Cell F NMR.

Li J, Wang Y, Distefano M, Wagner C, Pomerantz W Biomacromolecules. 2024; 25(2):1330-1339.

PMID: 38254252 PMC: 11375447. DOI: 10.1021/acs.biomac.3c01391.

Theranostics with photodynamic therapy for personalized medicine: to see and to treat.

Wang Y, Staudinger J, Mindt T, Gasser G Theranostics. 2023; 13(15):5501-5544.

PMID: 37908729 PMC: 10614685. DOI: 10.7150/thno.87363.

References

Idee J, Port M, Medina C, Lancelot E, Fayoux E, Ballet S . Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. Toxicology. 2008; 248(2-3):77-88. DOI: 10.1016/j.tox.2008.03.012. View

Blumfield E, Moore M, Drake M, Goodman T, Lewis K, Meyer L . Survey of gadolinium-based contrast agent utilization among the members of the Society for Pediatric Radiology: a Quality and Safety Committee report. Pediatr Radiol. 2017; 47(6):665-673. DOI: 10.1007/s00247-017-3807-z. View

Sherry A, Caravan P, Lenkinski R . Primer on gadolinium chemistry. J Magn Reson Imaging. 2009; 30(6):1240-8. PMC: 2853020. DOI: 10.1002/jmri.21966. View

Idee J, Port M, Robic C, Medina C, Sabatou M, Corot C . Role of thermodynamic and kinetic parameters in gadolinium chelate stability. J Magn Reson Imaging. 2009; 30(6):1249-58. DOI: 10.1002/jmri.21967. View

Ramalho J, Semelka R, Ramalho M, Nunes R, AlObaidy M, Castillo M . Gadolinium-Based Contrast Agent Accumulation and Toxicity: An Update. AJNR Am J Neuroradiol. 2015; 37(7):1192-8. PMC: 7960350. DOI: 10.3174/ajnr.A4615. View

Grobner T, Prischl F . Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure. Semin Dial. 2008; 21(2):135-9. DOI: 10.1111/j.1525-139X.2007.00406.x. View

Marckmann P, Skov L, Rossen K, Dupont A, Damholt M, Heaf J . Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006; 17(9):2359-62. DOI: 10.1681/ASN.2006060601. View

Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D . High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology. 2014; 270(3):834-41. DOI: 10.1148/radiol.13131669. View

Zhang Y, Cao Y, Shih G, Hecht E, Prince M . Extent of Signal Hyperintensity on Unenhanced T1-weighted Brain MR Images after More than 35 Administrations of Linear Gadolinium-based Contrast Agents. Radiology. 2016; 282(2):516-525. DOI: 10.1148/radiol.2016152864. View

10.

Ramalho J, Castillo M, AlObaidy M, Nunes R, Ramalho M, Dale B . High Signal Intensity in Globus Pallidus and Dentate Nucleus on Unenhanced T1-weighted MR Images: Evaluation of Two Linear Gadolinium-based Contrast Agents. Radiology. 2015; 276(3):836-44. DOI: 10.1148/radiol.2015150872. View

11.

Conte G, Preda L, Cocorocchio E, Raimondi S, Giannitto C, Minotti M . Signal intensity change on unenhanced T1-weighted images in dentate nucleus and globus pallidus after multiple administrations of gadoxetate disodium: an intraindividual comparative study. Eur Radiol. 2017; 27(10):4372-4378. DOI: 10.1007/s00330-017-4810-3. View

12.

Kanda T, Osawa M, Oba H, Toyoda K, Kotoku J, Haruyama T . High Signal Intensity in Dentate Nucleus on Unenhanced T1-weighted MR Images: Association with Linear versus Macrocyclic Gadolinium Chelate Administration. Radiology. 2015; 275(3):803-9. DOI: 10.1148/radiol.14140364. View

13.

Radbruch A, Weberling L, Kieslich P, Eidel O, Burth S, Kickingereder P . Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology. 2015; 275(3):783-91. DOI: 10.1148/radiol.2015150337. View

14.

Cao Y, Huang D, Shih G, Prince M . Signal Change in the Dentate Nucleus on T1-Weighted MR Images After Multiple Administrations of Gadopentetate Dimeglumine Versus Gadobutrol. AJR Am J Roentgenol. 2015; 206(2):414-9. DOI: 10.2214/AJR.15.15327. View

15.

Bae S, Lee H, Han K, Park Y, Choi Y, Ahn S . Gadolinium deposition in the brain: association with various GBCAs using a generalized additive model. Eur Radiol. 2017; 27(8):3353-3361. DOI: 10.1007/s00330-016-4724-5. View

16.

Langner S, Kromrey M, Kuehn J, Grothe M, Domin M . Repeated intravenous administration of gadobutrol does not lead to increased signal intensity on unenhanced T1-weighted images-a voxel-based whole brain analysis. Eur Radiol. 2017; 27(9):3687-3693. DOI: 10.1007/s00330-017-4777-0. View

17.

Kromrey M, Liedtke K, Ittermann T, Langner S, Kirsch M, Weitschies W . Intravenous injection of gadobutrol in an epidemiological study group did not lead to a difference in relative signal intensities of certain brain structures after 5 years. Eur Radiol. 2016; 27(2):772-777. DOI: 10.1007/s00330-016-4418-z. View

18.

Forslin Y, Shams S, Hashim F, Aspelin P, Bergendal G, Martola J . Retention of Gadolinium-Based Contrast Agents in Multiple Sclerosis: Retrospective Analysis of an 18-Year Longitudinal Study. AJNR Am J Neuroradiol. 2017; 38(7):1311-1316. PMC: 7959913. DOI: 10.3174/ajnr.A5211. View

19.

Stojanov D, Aracki-Trenkic A, Vojinovic S, Benedeto-Stojanov D, Ljubisavljevic S . Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based.... Eur Radiol. 2015; 26(3):807-15. DOI: 10.1007/s00330-015-3879-9. View

20.

Splendiani A, Perri M, Marsecano C, Vellucci V, Michelini G, Barile A . Effects of serial macrocyclic-based contrast materials gadoterate meglumine and gadobutrol administrations on gadolinium-related dentate nuclei signal increases in unenhanced T1-weighted brain: a retrospective study in 158 multiple sclerosis (MS).... Radiol Med. 2017; 123(2):125-134. DOI: 10.1007/s11547-017-0816-9. View